Drugs in liver disease

被引:18
作者
Branch, RA [1 ]
机构
[1] Univ Pittsburgh, Sch Med, Ctr Clin Pharmacol, Pittsburgh, PA 15260 USA
关键词
D O I
10.1016/S0009-9236(98)90077-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
引用
收藏
页码:462 / 465
页数:4
相关论文
共 13 条
[1]   Selective effect of liver disease on the activities of specific metabolizing enzymes: Investigation of cytochromes P450 2C19 and 2D6 [J].
Adedoyin, A ;
Arns, PA ;
Richards, WO ;
Wilkinson, GR ;
Branch, RA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (01) :8-17
[2]  
ADEDOYIN A, 1996, HEPATOLOGY TXB LIVER, V1, P307
[3]   Mephenytoin disposition and serum bile acids as indices of hepatic function in chronic viral hepatitis [J].
Arns, PA ;
Adedoyin, A ;
DiBisceglie, AM ;
Waggoner, JG ;
Hoofnagle, JH ;
Wilkinson, GR ;
Branch, RA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (05) :527-537
[4]   THE METABOLISM AND BIOAVAILABILITY OF MORPHINE IN PATIENTS WITH SEVERE LIVER-CIRRHOSIS [J].
HASSELSTROM, J ;
ERIKSSON, S ;
PERSSON, A ;
RANE, A ;
SVENSSON, JO ;
SAWE, J .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 29 (03) :289-297
[5]  
KRAUS JW, 1978, CLIN PHARMACOL THER, V24, P411
[6]  
KUBISTY CA, 1995, POCKET BOOK CRITICAL, P91
[7]   THE DISPOSITION OF DAPSONE IN CIRRHOSIS [J].
MAY, DG ;
ARNS, PA ;
RICHARDS, WO ;
PORTER, J ;
RYDER, D ;
FLEMING, CM ;
WILKINSON, GR ;
BRANCH, RA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (06) :689-700
[8]  
PATWARDHAN RV, 1981, GASTROENTEROLOGY, V81, P1006
[9]  
SHAND DG, 1978, LIVER QUANTITATIVE A, P346
[10]   GLUCURONIDATION OF OXAZEPAM IS NOT SPARED IN PATIENTS WITH HEPATIC-ENCEPHALOPATHY [J].
SONNE, J ;
ANDREASEN, PB ;
LOFT, S ;
DOSSING, M ;
ANDREASEN, F .
HEPATOLOGY, 1990, 11 (06) :951-956